{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:37:50Z","timestamp":1786538270347,"version":"build-2736575974"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Tetraphase Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n            Eravacycline is a novel, fully synthetic fluorocycline antibiotic with\n            <jats:italic>in vitro<\/jats:italic>\n            activity against aerobic and anaerobic Gram-positive and Gram-negative pathogens, including multidrug-resistant (MDR) bacteria. The pharmacokinetics (PK), urinary excretion, and safety\/tolerability of intravenous (i.v.) eravacycline were evaluated in single- and multiple-ascending-dose studies.\n          <\/jats:p>","DOI":"10.1128\/aac.01174-18","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T09:57:08Z","timestamp":1534931828000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline"],"prefix":"10.1128","volume":"62","author":[{"given":"Joseph V.","family":"Newman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Izmailyan","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Tsai","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06187-11"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2013-0292"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02403-15"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00366-16"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.022"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.73"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"e_1_3_2_16_2","volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Seng Yue C","year":"2010","unstructured":"Seng Yue C, Sutcliffe JA, Colucci P, Sprenger CR, Ducharme MP. 2010. Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration, abstr A1-028. Abstr 50th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/11317100-000000000-00000"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.220-229.2005"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"e_1_3_2_21_2","volume-title":"Abstr 52nd Intersci Conf Antimicrob Agents Chemother","author":"Ting L","year":"2012","unstructured":"Ting L, Kovacs SJ, Praestgaard J, Maietta R, Stein DS, Sunkara G, Draper MP, Sun H. 2012. Pharmacokinetics of omadacycline (PTK0796) in subjects with hepatic impairment, abstr A-1282. Abstr 52nd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.06.019"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00277-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01174-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01174-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:13:51Z","timestamp":1645478031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01174-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.01174-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01174-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01174-18"}}